Paper20046568
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
Lynch CM and 2 others. MAbs, 2009. Cited by 31 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. Papers, record 20046568. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20046568
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Guidelines as Topic | Major topic |
| Animals | |
| Drug Evaluation, Preclinical | |
| Humans | |
| Recombinant Proteins |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18,363,992 | Engineering therapeutic monoclonal antibodies. | Immunol Rev | 2008 | https://conductscience.org/library/papers/18363992 | PubMed |
| 2 | 29,451,320 | Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. | Br J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29451320 | PubMed |
| 3 | 16,107,258 | An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. | J Immunol Methods | 2005 | https://conductscience.org/library/papers/16107258 | PubMed |
| 4 | 12,826,605 | Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12826605 | PubMed |
| 5 | 16,299,896 | Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. | Clin Chem | 2005 | https://conductscience.org/library/papers/16299896 | PubMed |
| 6 | 12,509,759 | Therapeutic antibodies for human diseases at the dawn of the twenty-first century. | Nat Rev Drug Discov | 2003 | https://conductscience.org/library/papers/12509759 | PubMed |
| 7 | 9,676,753 | Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial. | J Rheumatol | 1998 | https://conductscience.org/library/papers/9676753 | PubMed |
| 8 | 10,734,150 | Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. | J Pharmacol Exp Ther | 2000 | https://conductscience.org/library/papers/10734150 | PubMed |
| 9 | 10,692,049 | Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required. | Immunology | 2000 | https://conductscience.org/library/papers/10692049 | PubMed |
| 10 | 15,230,298 | Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. | Lupus | 2004 | https://conductscience.org/library/papers/15230298 | PubMed |
| 11 | 8,638,281 | Immunotoxicity assessment of biotechnology products: a regulatory point of view. | Toxicology | 1995 | https://conductscience.org/library/papers/8638281 | PubMed |
| 12 | 16,822,577 | Antibody production. | Adv Drug Deliv Rev | 2006 | https://conductscience.org/library/papers/16822577 | PubMed |
| 13 | 16,908,486 | Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16908486 | PubMed |
| 14 | 16,622,479 | Potent antibody therapeutics by design. | Nat Rev Immunol | 2006 | https://conductscience.org/library/papers/16622479 | PubMed |
| 15 | 17,592,672 | Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. | Clin Breast Cancer | 2007 | https://conductscience.org/library/papers/17592672 | PubMed |
| 16 | 18,690,886 | The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. | Curr Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18690886 | PubMed |
| 17 | 17,038,473 | Natalizumab and progressive multifocal leucoencephalopathy. | Ann Rheum Dis | 2006 | https://conductscience.org/library/papers/17038473 | PubMed |
| 18 | 15,122,047 | Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges. | Mol Biotechnol | 2004 | https://conductscience.org/library/papers/15122047 | PubMed |
| 19 | 16,151,394 | Monoclonal antibody successes in the clinic. | Nat Biotechnol | 2005 | https://conductscience.org/library/papers/16151394 | PubMed |
| 20 | 15,947,082 | Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. | N Engl J Med | 2005 | https://conductscience.org/library/papers/15947082 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,610,927 | Overcoming Electrochemiluminescence Immunoassay (ECLIA) Limitations: Conformation-Independent Quantitation of a Therapeutic Antibody by LC-MS/MS. | Anal Chem | 2026 | https://conductscience.org/library/papers/42610927 | PubMed |
| 41,772,369 | QT Prolongation Risk of Antibody-Drug Conjugates. | Drug Saf | 2026 | https://conductscience.org/library/papers/41772369 | PubMed |
| 39,952,240 | Ligand-induced assembly of antibody variable fragments for the chemical regulation of biological processes. | Cell Chem Biol | 2025 | https://conductscience.org/library/papers/39952240 | PubMed |
| 38,348,660 | Immunocapture LC-MS methods for pharmacokinetics of large molecule drugs. | Bioanalysis | 2024 | https://conductscience.org/library/papers/38348660 | PubMed |
| 37,686,240 | Corneal Wound Healing in the Presence of Antifibrotic Antibody Targeting Collagen Fibrillogenesis: A Pilot Study. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37686240 | PubMed |
| 34,445,651 | The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34445651 | PubMed |
| 31,776,588 | Correlation between antidrug antibodies, pre-existing antidrug reactivity, and immunogenetics (MHC class II alleles) in cynomolgus macaque. | Immunogenetics | 2019 | https://conductscience.org/library/papers/31776588 | PubMed |
| 31,502,016 | Editorial: A Novel Monoclonal Antibody-Targeting Angiogenesis by Inhibiting Secreted Frizzled-Related Protein 2. | Ann Surg Oncol | 2019 | https://conductscience.org/library/papers/31502016 | PubMed |
| 30,469,350 | Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30469350 | PubMed |
| 30,320,117 | Regulatory Pathway for Licensing Biotherapeutics in Mexico. | Front Med (Lausanne) | 2018 | https://conductscience.org/library/papers/30320117 | PubMed |
| 30,021,009 | Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice. | PLoS One | 2018 | https://conductscience.org/library/papers/30021009 | PubMed |
| 28,154,831 | Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. | J Immunol Res | 2017 | https://conductscience.org/library/papers/28154831 | PubMed |
| 25,681,157 | The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment. | Curr Pain Headache Rep | 2015 | https://conductscience.org/library/papers/25681157 | PubMed |
| 23,774,668 | Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG. | MAbs | 2013 | https://conductscience.org/library/papers/23774668 | PubMed |
| 21,966,461 | A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. | PLoS One | 2011 | https://conductscience.org/library/papers/21966461 | PubMed |
| 21,822,050 | Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates. | MAbs | 2011 | https://conductscience.org/library/papers/21822050 | PubMed |
| 21,079,042 | Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. | Pharmacol Rev | 2010 | https://conductscience.org/library/papers/21079042 | PubMed |
| 20,421,713 | Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. | MAbs | 2010 | https://conductscience.org/library/papers/20421713 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20046568
GET https://conductscience.org/api/papers/v1/20046568/references?page=2